Pharma Firms Can Sue Competitors For Violating Orphan Exclusivity, German Court Rules
Executive Summary
A German civil court has ruled that pharma firms can enforce market exclusivity rights for orphan drugs by taking legal action against competitors. Lawyers say this decision, which relates to Alexion’s Soliris, is the first of its kind and will likely have a wider impact across the EU.
You may also be interested in...
EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives
The EU’s regulatory reform package if unchanged could make orphan drug development less attractive, warn industry representatives.
Amgen Chooses To Settle In US Soliris IPR Tussle
Amgen’s burgeoning biosimilar presence continues to grow apace and now the company has eyes firmly on the US market for eculizumab after brokering a deal with originator Alexion. The biosimilars developer chose to settle on three of Alexion’s patents ahead of a trial later this year.
EU Needs Better Data Tools To Combat Vaccine-Preventable Cancers, Says Industry
Data on vaccine coverage rates and trends in vaccine-preventable disease incidence in the EU are crucial but are often not available or inaccurate, according to EFPIA subgroup Vaccines Europe.